The open-access journal, PLoS NTDs, celebrated its fifth anniversary. To commemorate this great achievement, the journal compiled editorials and research papers published over the last five years to create a collection, called “The Geopolitics of NTDs.”
The collection focuses on the geographic distribution of NTDs by region to highlight the key differences as well as similarities between the diseases in different areas around the world.
October 11, 2012 | Financial Times
The Financial Times special report “Combating Neglected Diseases” contains in-depth stories and interviews featuring several of Sabin’s key programs, including Sabin Vaccine Development, the Global Network for Neglected Tropical Diseases and the Dengue Vaccine Initiative.
Read the full report here.
The Schistosomiasis Vaccine Initiative was launched in 2008 through funding from Mr. Morton Hyman and the Blavatnik Family Foundation. In collaboration with researchers at James Cook University and The George Washington University, a promising antigen, Sm-TSP-2, was selected for development.
Schistosomiasis is a parasite carried by snails and transmitted through contact with contaminated fresh water sources such as lakes, ponds, rivers and dams. Schistosomiasis infection is readily transmissible for those who come in frequent contact with contaminated water – particularly children who wade or play in water and women conducting domestic chores.
In collaboration with researchers at the James Cook University and The George Washington University, a promising new antigen, Sm-TSP-2 (Schistosoma mansoni Tetraspanin-2), was selected for development as a schistosomiasis vaccine. Then at Texas Children's Hospital and Baylor College of Medicine, Sabin and its partners developed the process for manufacture of the vaccine under cGMP, and was followed by technology transfer to Sabin's manufacturing partner, Aeras.
Schistosomiasis afflicts over 250 million people around the globe and is the deadliest disease among the seven most prevalent NTDs, killing an estimated 280,000 people annually. Thanks to private donations from Mr. Morton Hyman, Dr. Gary Michelson, Texas Children’s Hospital and the Blavatnik Family Foundation, the Schistosomiasis Vaccine Initiative (SVI) utilizes and leverages the Sabin Vaccine Institute PDP’s existing programmatic and technical infrastructure to produce and evaluate a schistosomiasis vaccine.
Sabin’s diverse partnerships are important to achieving the organization’s mission. The Sabin Vaccine Institute Product Development Partnership (Sabin PDP) leverages the expertise of partners in the academic, public and private sectors and promotes open-source research that focuses on capacity building, infrastructure development and knowledge sharing. To advance product development, we are working with institutions in Europe, Brazil, Malaysia and Mexico to expand product development and manufacturing capabilities to develop new vaccines.
With over a decade of experience, Sabin PDP has produced a well-rounded model that serves as a blueprint for the development of safe and effective vaccines against vaccine preventable and neglected tropical diseases. Existing capabilities include:
Product Development: Established the infrastructure to engage in antigen discovery, rapid development of scalable manufacturing processes (process development), quality control, preclinical and clinical immunology and stability testing.